Corbus Pharmaceuticals to Report Fourth Quarter and Year-End 2020 Results on March 15, 2021
March 08 2021 - 8:05AM
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or
the “Company”), a clinical-stage drug development company
pioneering transformative medicines that target the endocannabinoid
system, today announced that it will report its fourth quarter and
year-end financial results on Monday, March 15th. Corbus management
will host a conference call and live audio webcast to discuss the
operational and financial results at 8:30 a.m. ET that same day.
The call will be led by Yuval Cohen, Ph.D., Chief Executive Officer
of Corbus, who will be joined by additional members of the Corbus
management team. Interested participants and investors may access
the conference call by dialing (877) 407-3978 (domestic) or (412)
902-0039 (international). The live webcast will be accessible on
the Events page of the Investors section of the Corbus website,
www.corbuspharma.com and will be archived for 90 days Following the
event.
About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a
clinical-stage company focused on the development and
commercialization of novel medicines designed to target the
endocannabinoid system. The Company’s lead product
candidate, lenabasum, is a novel, oral, selective cannabinoid
receptor type 2 (CB2) agonist that resolves chronic inflammation
and limits fibrosis in animal and human
models. Lenabasum is currently being evaluated in
dermatomyositis and systemic lupus erythematosus. Corbus is also
developing a pipeline of other preclinical drug candidates from its
endocannabinoid system platform.
Lenabasum is not approved for the treatment of any indication.
For more information on Corbus’ clinical programs, please
visit here.
For more information, visit http://www.corbuspharma.com/,
and connect with us on Twitter, LinkedIn,
and Facebook.
Forward-Looking Statements
This press release contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934 and Private Securities Litigation Reform Act, as
amended, including those relating to the Company’s product
development, clinical and regulatory timelines, market opportunity,
competitive position, possible or assumed future results of
operations, business strategies, potential growth opportunities and
other statement that are predictive in nature. These
forward-looking statements are based on current expectations,
estimates, forecasts and projections about the industry and markets
in which we operate and management’s current beliefs and
assumptions.
These statements may be identified by the use of
forward-looking expressions, including, but not limited to,
“expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,”
“potential,” “predict,” “project,” “should,” “would” and similar
expressions and the negatives of those terms. These statements
relate to future events or our financial performance and involve
known and unknown risks, uncertainties, and other factors which may
cause actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements. Such
factors include those set forth in the Company’s filings with the
Securities and Exchange Commission. Prospective investors are
cautioned not to place undue reliance on such forward-looking
statements, which speak only as of the date of this press release.
The Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise.
Corbus Pharmaceuticals Contacts: Ted Jenkins,
Senior Director, Investor Relations and Corporate Communications
Phone: +1 (617) 415-7745 Email: ir@corbuspharma.com
Lindsey Smith, Director, Investor Relations and Corporate
Communications Phone: +1 (617) 415-7749 Email:
mediainfo@corbuspharma.com
Corbus Pharmaceuticals (NASDAQ:CRBP)
Historical Stock Chart
From Jul 2024 to Aug 2024
Corbus Pharmaceuticals (NASDAQ:CRBP)
Historical Stock Chart
From Aug 2023 to Aug 2024